Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[alpha]anthracene-induced breast tumor in rat

Food Chem Toxicol. 2010 Jun;48(6):1587-91. doi: 10.1016/j.fct.2010.03.029. Epub 2010 Mar 21.

Abstract

Centchroman is a non-steroidal oral contraceptive and has been found to be a candidate drug for breast cancer exhibiting partial to complete remission of lesions in 40.5% of breast cancer patients. The therapeutic efficacy of centchroman was monitored alone and together with glycine soya on growth of 7,12-dimethylbenz[alpha]anthracene-induced breast tumor in rat. The tumor regression was monitored at different doses of centchroman alone ranging from 0 to 10 mg kg(-1) and with glycine soya from 1x10(4) to 5x10(4) mg kg(-1) per day until 5weeks treatment. An optimum tumor treatment opus was established with varying treatment parameters including doses of therapeutic agents and treatment period. The tumors were found to be static with a strong anti-estrogenic effect. Overall our study shows that both centchroman and glycine soya alone and jointly combat with breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 9,10-Dimethyl-1,2-benzanthracene / toxicity*
  • Animals
  • Apoptosis
  • Carcinogens / toxicity*
  • Cell Proliferation
  • Centchroman / administration & dosage
  • Centchroman / therapeutic use*
  • Estrogen Antagonists / administration & dosage
  • Estrogen Antagonists / therapeutic use*
  • Female
  • Glycine max*
  • Mammary Neoplasms, Experimental / chemically induced
  • Mammary Neoplasms, Experimental / drug therapy*
  • Mammary Neoplasms, Experimental / pathology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Estrogen / metabolism

Substances

  • Carcinogens
  • Estrogen Antagonists
  • Receptors, Estrogen
  • Centchroman
  • 9,10-Dimethyl-1,2-benzanthracene